Business
Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms
Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms.
About this update from Medical Care Technologies Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms\r\n \r\n \r\n\r\n\r\nMedical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms\r\n\r\n\r\n\r\n\r\n\r\nMESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a marked rise in trading activity and shareholder engagement as the Company transitions into a new phase of technology-driven growth and leaves behind dilution tied to its previous Regulation A offering. \r\n \r\n Over recent trading sessions, MDCE has experienced substantial increases in both share price and trading volume, signaling renewed attention from retail and strategic investors tracking the Company's emerging footprint in the high-growth AI health-technology sector.\r\n This shift aligns with the Company's accelerated development of artificial intelligence tools-particularly its Google-backed AI dermatology and wound-monitoring platform, designed to support early detection of melanoma and the remote management of chronic wounds for millions of patients globally.\r\n \"This renewed momentum reflects a clear vote of confidence in our direction and in the future we're building,\" stated CEO Marshall Perkins III.\"With dilution from our prior Reg A ending and new AI partnerships propelling us forward, MDCE is entering an exciting era of innovation and value creation.\"\r\n Growth Drivers Supporting Investor Excitement\r\n MDCE attributes this increasing market interest to several key catalysts:\r\n • Conclusion of Reg A dilution - creating a more stable and attractive share structure• New AI-health technology integrations - including melanoma-detection capabilities• Accelerated product development timelines• Expansion of technical advisory and integration collaboration efforts• Growing visibility across the investor community\r\n Together, these advancements establish a strong foundation as MDCE scales toward consumer testing, commercialization, and long-term revenue execution.\r\n Positioned to Capture Major Market Opportunities\r\n With dermatology and wound-care markets representing a combined multi-billi...